Mark S. Freedman
Mark S. Freedman
University of Ottawa
Verified email at
Cited by
Cited by
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
AJ Thompson, BL Banwell, F Barkhof, WM Carroll, T Coetzee, G Comi, ...
The Lancet Neurology 17 (2), 162-173, 2018
Defining the clinical course of multiple sclerosis: the 2013 revisions
FD Lublin, SC Reingold, JA Cohen, GR Cutter, PS S°rensen, ...
Neurology 83 (3), 278-286, 2014
Randomized trial of oral teriflunomide for relapsing multiple sclerosis
P O'Connor, JS Wolinsky, C Confavreux, G Comi, L Kappos, TP Olsson, ...
New England Journal of Medicine 365 (14), 1293-1303, 2011
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L Kappos, CH Polman, MS Freedman, G Edan, HP Hartung, DH Miller, ...
Neurology 67 (7), 1242-1249, 2006
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double‐blind placebo‐controlled multicenter trial
K Hawker, P O'Connor, MS Freedman, PA Calabresi, J Antel, J Simon, ...
Annals of neurology 66 (4), 460-471, 2009
Differential diagnosis of suspected multiple sclerosis: a consensus approach
DH Miller, BG Weinshenker, M Filippi, BL Banwell, JA Cohen, ...
Multiple Sclerosis Journal 14 (9), 1157-1174, 2008
A full genome search in multiple sclerosis
GC Ebers, K Kukay, DE Bulman, AD Sadovnick, G Rice, C Anderson, ...
Nature genetics 13 (4), 472-476, 1996
Quantifying axonal loss after optic neuritis with optical coherence tomography
F Costello, S Coupland, W Hodge, GR Lorello, J Koroluk, YI Pan, ...
Annals of Neurology: Official Journal of the American Neurologicalá…, 2006
Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of theá…
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet 370 (9585), 389-397, 2007
Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis
M Duddy, M Niino, F Adatia, S Hebert, M Freedman, H Atkins, HJ Kim, ...
The Journal of Immunology 178 (10), 6092-6099, 2007
Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement
MS Freedman, EJ Thompson, F Deisenhammer, G Giovannoni, ...
Archives of neurology 62 (6), 865-870, 2005
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
L Kappos, A Bar-Or, BAC Cree, RJ Fox, G Giovannoni, R Gold, ...
The Lancet 391 (10127), 1263-1273, 2018
Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
C Confavreux, P O'Connor, G Comi, MS Freedman, AE Miller, TP Olsson, ...
The Lancet Neurology 13 (3), 247-256, 2014
Vitamin D as an early predictor of multiple sclerosis activity and progression
A Ascherio, KL Munger, R White, K K÷chert, KC Simon, CH Polman, ...
JAMA neurology 71 (3), 306-314, 2014
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
PW O’connor, D Li, MS Freedman, A Bar-Or, GPA Rice, C Confavreux, ...
Neurology 66 (6), 894-900, 2006
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3á…
L Kappos, MS Freedman, CH Polman, G Edan, HP Hartung, DH Miller, ...
The Lancet Neurology 8 (11), 987-997, 2009
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study
B Banwell, L Krupp, J Kennedy, R Tellier, S Tenembaum, J Ness, ...
The Lancet Neurology 6 (9), 773-781, 2007
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ...
The Lancet 387 (10023), 1075-1084, 2016
Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
KC O'Connor, KA McLaughlin, PL De Jager, T Chitnis, E Bettelli, C Xu, ...
Nature medicine 13 (2), 211-217, 2007
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
P Vermersch, A Czlonkowska, LME Grimaldi, C Confavreux, G Comi, ...
Multiple Sclerosis Journal 20 (6), 705-716, 2014
The system can't perform the operation now. Try again later.
Articles 1–20